Arrivent announces first patient dosed with ARR-002 dual-target ADC
AVBP•ArriVent BioPharma announced that the first patient has been dosed with ARR-002, a tetravalent MUC16/NAPI2B dual-target ADC.
1. First patient dosed
ArriVent BioPharma announced the first patient has been dosed with ARR-002, described as a novel tetravalent MUC16/NAPI2B dual-target ADC.
